Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $63.42 USD
Change Today +0.28 / 0.44%
Volume 3.4M
ENDP On Other Exchanges
As of 8:10 PM 10/8/15 All times are local (Market data is delayed by at least 15 minutes).

endo international plc (ENDP) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/16/15 - $96.58
52 Week Low
10/15/14 - $57.14
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

endo international plc (ENDP) Details

Endo International plc, a specialty healthcare company, focuses on branded and generic pharmaceuticals and devices worldwide. It operates through four segments: U.S. Branded Pharmaceuticals, U.S. Generic Pharmaceuticals, Devices, and International Pharmaceuticals. The U.S. Branded Pharmaceuticals segment provides various branded prescription products, including Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Fortesta Gel, Supprelin LA, Valstar, Vantas, Sumavel DosePro, Aveed, and Natesto to treat and manage pain and conditions in urology, endocrinology, and oncology. The U.S. Generic Pharmaceuticals segment offers products in the pain management, urology, CNS disorders, immunosuppression, oncology, women’s health, hypertension, generic lidocaine patch, and other markets. The Devices segment provides various medical devices comprising AMS 800 artificial urinary sphincters, AMS 700 MS series, Monarc subfascial hammock products, Elevate anterior and posterior pelvic floor repair systems, and GreenLight XPS laser systems in the areas of men’s and women’s pelvic health. The International Pharmaceuticals segment offers Dexedrine, Tridural, Metadol, Trandate, Pennsaid, and Plan B products in therapeutic areas, including attention deficit hyperactivity disorder, pain, urology, and allergy. It sells its branded pharmaceuticals and generics directly to large pharmacy chains; and through wholesale drug distributors to pharmacies, hospitals, governmental agencies, and physicians. Endo International plc was founded in 1920 and is headquartered in Dublin, Ireland.

5,062 Employees
Last Reported Date: 03/2/15
Founded in 1920

endo international plc (ENDP) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $1.1M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $835.8K
Total Annual Compensation: $576.2K
Compensation as of Fiscal Year 2014.

endo international plc (ENDP) Key Developments

Endo International plc Provides Earnings Guidance for the Twelve Months Ending December 31, 2015 and for the Full Year 2016

Endo International plc provided earnings guidance for the full twelve months ending December 31, 2015. Total revenue to be between $3.22 billion and $3.27 billion; and adjusted diluted EPS from continuing operations to be between $4.50 and $4.60 compared to $4.40 and $4.60 estimated in previous guidance. Adjusted effective tax rate of between 9% and 10%; and Adjusted diluted earnings per share from continuing operations assume full year diluted shares outstanding of approximately $201 million. For full year 2016, the company estimates adjusted diluted EPS from continuing operations to be between $5.85 and $6.15.

Endo International plc Provides Earning Guidance for the Third Quarter of 2015

Endo International plc provided earning guidance for the third quarter of 2015. The company expects third quarter 2015 revenues to be between $720 million and $740 million. On an adjusted basis, the company expects third quarter 2015 gross margin and operating expenses to be within previous full year guidance ranges as a percentage of revenues. The company do not expect the net operating results for third quarter from Par to be material. However, the timing of Par-related financing activities will have a material impact on results below the operating line. The company expects adjusted interest expense in the third quarter 2015 to be approximately $95 million. The closing of the Par transaction in the third quarter creates timing benefits around the utilization of certain tax attributes that lead to an effective tax rate in the quarter of approximately 2% to 4%.

Endo International plc Appoints Paul Campanelli to Lead Par Pharmaceutical

Endo International plc announced it has completed its previously announced $8.05 billion acquisition of Par Pharmaceutical Holdings Inc. Endo's combined U.S. Generics segment, which includes Par Pharmaceutical and Qualitest, will be named Par Pharmaceutical, an Endo International Company and will be led by Paul Campanelli, former Chief Executive Officer of Par Pharmaceutical, who will also join Endo's Executive Leadership Team.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ENDP:US $63.42 USD +0.28

ENDP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Actelion Ltd SFr.118.70 CHF +0.10
CR Bard Inc $187.02 USD +0.20
Edwards Lifesciences Corp $146.27 USD +0.99
Hologic Inc $37.20 USD -0.28
UCB SA €68.17 EUR +0.03
View Industry Companies

Industry Analysis


Industry Average

Valuation ENDP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 3.6x
Price/Book 2.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.9x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ENDO INTERNATIONAL PLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at